Hasil Pencarian (1)
small molecule | CAS: 1792180-81-4
Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adul…
Kategori:
Antineoplastic and Immunomodulating AgentsCytochrome P-450 CYP1A2 InhibitorsCytochrome P-450 CYP1A2 Inhibitors (strength unknown)
+16
Target Protein:
Tyrosine-protein kinase JAK3Tyrosine-protein kinase TecTyrosine-protein kinase ITK/TSK
+3
Waktu ParuhRitlecitinib has a …
Vol. DistribusiRitlecitinib is pre…
KlirensRitlecitinib is pre…
Genetik
-